BiotechTube

Diclofenac sodium topical gel 1% + Placebo

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Ankle Sprain

Conditions

Ankle Sprain

Trial Timeline

Nov 1, 2010 → Jun 1, 2011

NCT ID
NCT01255423

About Diclofenac sodium topical gel 1% + Placebo

Diclofenac sodium topical gel 1% + Placebo is a phase 3 stage product being developed by Novartis for Ankle Sprain. The current trial status is completed. This product is registered under clinical trial identifier NCT01255423. Target conditions include Ankle Sprain.

What happened to similar drugs?

3 of 6 similar drugs in Ankle Sprain were approved

Approved (3) Terminated (0) Active (3)
✅Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
✅diclofenac potassium 25 mg tablet + placeboNovartisApproved
🔄Diclofenac SodiumNovartisPhase 3
🔄diclofenac diethylamine gel 2.32% + diclofenac diethylamine gel 2.32% + PlaceboNovartisPhase 3
✅Non-selective NSAIDS + CelecoxibPfizerApproved
🔄Topical IBU twice daily + Placebo twice daily + Topical IBU three times daily + Placebo three times dailyPfizerPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01255423Phase 3Completed

Competing Products

7 competing products in Ankle Sprain

See all competitors
ProductCompanyStageHype Score
Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
44
diclofenac potassium 25 mg tablet + placeboNovartisApproved
43
Diclofenac SodiumNovartisPhase 3
40
Diclofenac diethylamine 2.32% gel + Placebo + Diclofenac diethylamine 2.32% gel / PlaceboNovartisPhase 2
35
diclofenac diethylamine gel 2.32% + diclofenac diethylamine gel 2.32% + PlaceboNovartisPhase 3
40
Non-selective NSAIDS + CelecoxibPfizerApproved
43
Topical IBU twice daily + Placebo twice daily + Topical IBU three times daily + Placebo three times dailyPfizerPhase 3
40